2005 Cardiovascular Biomarkers and Surrogate Endpoints Symposium
Assessing Cardiovascular Risk and Progression
September 23-24, 2005 Bethesda, Maryland
CO-CHAIRS:
Peter Libby, M.D., Mallinckrodt Professor of Medicine Harvard Medical School and Chief Cardiovascular Medicine Brigham and Women’s Hospital Boston, Massachusetts;
Jean-Claude Tardif, M.D., FRCPC, FACC, Director, MHI Research Center Associate Professor of Medicine CIHR Chair in Atherosclerosis Montreal Heart Institute Montreal, Quebec
Welcome and Conference Objectives - Dr. Jean-Claude Tardif and Dr. Therese Heinonen
Pathogenesis of Atherothrombotic Disease and Biomarker identification - Dr. Peter Libby
Is CRP a Validated Biomarker of CV Disease? - Dr. Paul Ridker
The Role of Imaging in Disease Detection and Treatment - Dr. Jean-Claude Tardif
Markers of Aging and Dementia - Dr. Lewis Kuller
Questions and Answers- Faculty
The Need for Biomarkers in Drug Development - Dr. Bill Sasiela
The FDA Critical Path Initiative – Opportunities and Challenges - Dr. Douglas Throckmorton
How Does the FDA Metabolism and Endocrine Department View Surrogate Endpoints? - Dr. David Orloff
Questions and Answers – Faculty and PANEL DISCUSSION
The role of Lipoproteins in Inflammation - Dr. Philip Barter
Oxidation in the Pathogenesis of Atherosclerosis - Dr. Jay Heinecke
Special Considerations in Diabetes and Metabolic Syndrome - Dr. Steven Haffner
Opportunities for the use of Biomarkers and Surrogate endpoints in the European Union - Dr. Eric Abadie
The Balance Between Safety and Efficacy: Biomarkers as Safety Surrogates - Dr. Eric Brass
Questions and Answers – Faculty and PANEL DISCUSSION
Summary and Introduction - Dr. Jean-Claude Tardif and Dr. Peter Libby
Diagnostic and Therapeutic Synergies - Dr. Donald Black
Current Status of Disease Assessment with Carotid Ultrasound - Dr. Allen Taylor
IVUS As a Surrogate Endpoint - Dr. Steve Nissen
Palpography and Elastography as Biomarkers of Cardiovascular Disease - Dr. Ton van der Steen
Advances in Cardiovascular Imaging - Dr. Minh Nguyen
Questions and Answers- Faculty
Combined Blood Biomarkers: Diminishing Returns or are More Better - Dr. Wolfgang Koenig
Applying Genomics, Proteomics and Metabolomics Technology to Development Programs - Dr. Michael Phillips
Questions and Answers – Faculty and PANEL DISCUSSIONS
Summary of 2 day Breakout Sessions (Session Leaders)
How should pharmacogenomics be used prospectively in clinical studies of drug safety and efficacy?
The future of diagnostics – who are the drivers?
How can we maximize the application and utility of safety biomarkers?
How should biomarkers be used in pre-clinical modeling and early dose selection?
What is a rational approach to biomarker validation?
How do you develop a drug that does not target an accepted surrogate endpoint?
Vascular imaging technologies – technical and clinical considerations?
Questions and Answers – Faculty and PANEL DISCUSSIONS
Closing Remarks - Dr. Peter Libby and Dr. Jean-Claude Tardif